Organizational Chart International Technology Transfer General Information Career Opportunities


Spacer

 
Licensing & Royalties
spacer
 

Licensing Opportunities

Technology Abstracts

Print This Abstract Apply Questions ?
Identification of Biomarkers by Serum Protein Profiling

Description of Invention:
This invention describes serum features that distinguish colorectal carcinoma malignant patient samples versus healthy samples using surface-enhanced laser desorption ionization time-of-flight (SELDI-TOF) mass spectrometry. By comparing healthy versus malignant samples, the investigators were able to identify thirteen (13) serum features that have been validated using an independently collected, blinded validation set of 55 sera samples. The features are characterized by the mass to charge ratio (m/z ratio). The investigators have shown that SELDI-TOF based serum marker protein profiling enables minimally invasive detection of colon cancer with 96.7 percent sensitivity and 100 percent specificity.

Colorectal cancer is the third most common cancer and the third leading cause of cancer-related mortality in the United States. Current diagnostic methods for colorectal cancer have a large non-compliance rate because of discomfort, e.g., sigmoidoscopy or colonoscopy, or have a high rate of false positive results, e.g., fecal occult blood tests. The claimed invention has the potential to be a widely used, easy-to-use, and inexpensive diagnostic.

Inventors:
Thomas Ried and Jens Habermann (NCI)

Patent Status:
DHHS Reference No. E-106-2005/0 --
U.S. Provisional Application No. 60/664,681 filed 22 Mar 2005
PCT Application No. PCT/US2006/010624 filed 22 Mar 2006, which published as WO 2006/102526 on 26 Sep 2006
U.S. Patent Application No. 11/886,886 filed 21 Sep 2007

Licensing Status:
In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.


Portfolios:
Cancer

Cancer -Diagnostics-In Vitro-Other
Cancer -Therapeutics-Conventional Chemotherapy-Alkylating Agents
Cancer -Therapeutics-Conventional Chemotherapy-Alkaloids
Cancer -Diagnostics
Cancer -Therapeutics


For Additional Information Please Contact:
Surekha Vathyam Ph.D.
Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/435-4076
Email: vathyams@mail.nih.gov
Fax: 301/402-0220


Web Ref: 1300

Updated: 2/06

 

 
 
Spacer